BRPI0616703A2 - forma de dosagem farmacêutica - Google Patents
forma de dosagem farmacêuticaInfo
- Publication number
- BRPI0616703A2 BRPI0616703A2 BRPI0616703A BRPI0616703A BRPI0616703A2 BR PI0616703 A2 BRPI0616703 A2 BR PI0616703A2 BR PI0616703 A BRPI0616703 A BR PI0616703A BR PI0616703 A BRPI0616703 A BR PI0616703A BR PI0616703 A2 BRPI0616703 A2 BR PI0616703A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage form
- pharmaceutical dosage
- pharmaceutical
- dosage
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/239,249 US8007827B2 (en) | 2004-04-02 | 2005-09-30 | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
| PCT/US2006/036694 WO2007040997A2 (en) | 2005-09-30 | 2006-09-20 | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0616703A2 true BRPI0616703A2 (pt) | 2016-09-06 |
Family
ID=37906654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0616703A BRPI0616703A2 (pt) | 2005-09-30 | 2006-09-20 | forma de dosagem farmacêutica |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8007827B2 (pt) |
| EP (1) | EP1940361B1 (pt) |
| JP (1) | JP5366549B2 (pt) |
| KR (1) | KR20080059409A (pt) |
| CN (1) | CN101312716A (pt) |
| AU (1) | AU2006297477B2 (pt) |
| BR (1) | BRPI0616703A2 (pt) |
| CA (1) | CA2625481C (pt) |
| ES (1) | ES2561585T3 (pt) |
| TR (1) | TR200804209T1 (pt) |
| TW (1) | TW200735899A (pt) |
| WO (1) | WO2007040997A2 (pt) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013202441B2 (en) * | 2006-04-26 | 2016-02-25 | Alphapharm Pty Ltd | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix |
| HUE029173T2 (hu) * | 2006-04-26 | 2017-02-28 | Alphapharm Pty Ltd | Szabályozott hatóanyag-leadású készítmények, amelyek tartalmaznak nem bevont diszkrét egység(ek)et és egy késleltetett hatóanyag-leadású mátrixot |
| GB2443738A (en) * | 2006-11-09 | 2008-05-14 | Proprius Pharmaceuticals Inc | A sustained release methotrexate composition and methods of use thereof |
| US20080268045A1 (en) * | 2006-11-09 | 2008-10-30 | Proprius Pharmaceuticals, Inc. | Sustained release methotrexate formulations and methods of use thereof |
| WO2009085306A1 (en) | 2007-12-28 | 2009-07-09 | Impax Laboratories, Inc. | Controlled release formulations of levodopa and uses thereof |
| US9248119B2 (en) | 2010-06-16 | 2016-02-02 | Takeda Pharmaceuticals U.S.A., Inc. | Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors |
| US8685947B2 (en) * | 2010-08-25 | 2014-04-01 | Brown University | Compositions and methods for loop diuretics with consistent bioavailability |
| CN102416170B (zh) * | 2011-11-07 | 2013-08-07 | 重庆申高生化制药有限公司 | 多酶片的生产工艺 |
| US9498441B2 (en) * | 2012-01-27 | 2016-11-22 | Siegfried Rhein S.A. De C.V. | Nitazoxadine composition and process to prepare same |
| US20140106026A1 (en) * | 2012-10-16 | 2014-04-17 | Raphael Wald | Article and method for treating, preventing and ameliorating alcohol-induced wernicke-korsakoff syndrome |
| US9289418B2 (en) | 2013-03-15 | 2016-03-22 | Cedars-Sinai Medical Center | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens |
| HK1214752A1 (zh) | 2013-03-15 | 2016-08-05 | Cedars-Sinai Medical Center | 由产甲烷菌引起或与之相关的疾病及病状的诊断、选择及治疗方法 |
| EP3782614A1 (en) | 2013-10-07 | 2021-02-24 | Impax Laboratories, LLC | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| KR101561345B1 (ko) * | 2013-10-17 | 2015-10-16 | 대원제약주식회사 | 제어방출되는 프로피온산 계열의 약제학적 조성물 |
| BR112017002761A2 (pt) | 2014-08-13 | 2017-12-19 | Cedars Sinai Medical Center | composições anti-metanogênicas e usos das mesmas |
| US10172800B2 (en) | 2015-02-20 | 2019-01-08 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form with enhanced pharmacokinetics |
| US10987328B2 (en) | 2015-02-20 | 2021-04-27 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
| US10300032B2 (en) | 2015-02-20 | 2019-05-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
| WO2016132233A1 (en) | 2015-02-20 | 2016-08-25 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release oral dosage form of gaba receptor agonist with enhanced pharmacokinetics |
| KR20160105662A (ko) * | 2015-02-27 | 2016-09-07 | 대원제약주식회사 | 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물 |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| EP3277317A1 (en) | 2015-03-31 | 2018-02-07 | VHsquared Limited | Peptide construct having a protease-cleavable linker |
| WO2016161085A1 (en) | 2015-04-01 | 2016-10-06 | Cedars-Sinai Medical Center | Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
| US20180368458A1 (en) * | 2016-02-17 | 2018-12-27 | Corr-Jensen Inc. | Time release vitamins and minerals in edible oils |
| CN105748444B (zh) * | 2016-03-30 | 2018-08-31 | 济南康和医药科技有限公司 | 一种双相释放的头孢妥仑匹酯制剂及其制备方法 |
| WO2017167997A1 (en) | 2016-03-31 | 2017-10-05 | Vhsquared Limited | Compositions |
| CN108822816A (zh) * | 2018-06-25 | 2018-11-16 | 中国石油集团渤海钻探工程有限公司 | 一种疏松砂岩用可酸溶凝胶堵漏剂及其制备方法 |
| CN114466864B (zh) | 2019-06-21 | 2024-12-27 | 索瑞索制药公司 | 多肽 |
| KR20220064953A (ko) | 2019-06-21 | 2022-05-19 | 소리소 파마슈티컬스 인크. | 폴리펩티드 |
| CN113018273B (zh) * | 2019-12-25 | 2024-08-09 | 上海宣泰医药科技股份有限公司 | 一种固体制剂及其制备方法和用途 |
| EP3854385A1 (en) | 2020-01-27 | 2021-07-28 | ROS Therapeutics ApS | Methotrexate dosage form |
| HUE067496T2 (hu) | 2020-12-08 | 2024-10-28 | Ruminant Biotech Corp Ltd | Az állatoknak szánt anyagok bejuttatására szolgáló eszközök és módszerek fejlesztése |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| EP4267113A4 (en) | 2020-12-22 | 2025-02-12 | Amneal Pharmaceuticals LLC | LEVODOPA DOSING SCHEME |
| EP4340838A4 (en) * | 2021-05-19 | 2025-04-16 | Alberto Paz | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT |
| CN117137877A (zh) * | 2023-10-09 | 2023-12-01 | 重庆士立德医药科技有限公司 | 一种巴氯芬缓释片及其制备方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL270408A (pt) * | 1960-10-20 | |||
| JPS5852219A (ja) * | 1981-09-22 | 1983-03-28 | Sumitomo Chem Co Ltd | パ−キンソン病治療剤 |
| US4764380A (en) | 1982-03-22 | 1988-08-16 | Alza Corporation | Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills |
| US4780463A (en) * | 1984-12-26 | 1988-10-25 | Analgesic Associates | Analgesic, anti-inflammatory and skeletal muscle relaxant compositions comprising non-steroidal anti-inflammatory drugs and musculoskeletal relaxants and methods of using same |
| US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
| IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
| PH26730A (en) * | 1988-12-30 | 1992-09-28 | Ciba Geigy Ag | Coated adhesive tablets |
| US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5229131A (en) | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| US5686105A (en) * | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| GB9308430D0 (en) | 1993-04-23 | 1993-06-09 | Glaxo Group Ltd | Medicaments |
| JPH072650A (ja) * | 1993-06-18 | 1995-01-06 | Tanabe Seiyaku Co Ltd | 放出部位制御型製剤 |
| DE4406424A1 (de) | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandierbare Arzneiformen |
| ES2163504T5 (es) | 1994-05-06 | 2008-05-16 | Pfizer Inc. | Formas de dosificacion de liberacion controlada de azitromicina. |
| US6156343A (en) | 1994-12-27 | 2000-12-05 | Akzo Nobel N.V. | Controlled release preparation |
| IT1282576B1 (it) * | 1996-02-06 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili |
| SE9603408D0 (sv) | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| CA2275604A1 (en) | 1997-01-03 | 1998-07-09 | Kenneth Iain Cumming | Sustained release cisapride mini-tablet formulation |
| US7119189B2 (en) * | 1997-03-19 | 2006-10-10 | Novartis Ag | Metabotropic GABA [B] receptors, receptor-specific ligands and their uses |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6262066B1 (en) * | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| WO2000024423A1 (en) | 1998-10-26 | 2000-05-04 | Tanabe Seiyaku Co., Ltd. | Sustained-release particles |
| RU2236847C2 (ru) | 1998-11-02 | 2004-09-27 | Илан Корпорейшн, Плк. | Композиции в виде множества частиц с модифицированным высвобождением |
| US6419960B1 (en) * | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| WO2000050034A1 (en) | 1999-02-24 | 2000-08-31 | The Regents Of The University Of California | Gaba receptors mediate inhibition of t cell responses |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| JP2001055322A (ja) * | 1999-08-18 | 2001-02-27 | Tanabe Seiyaku Co Ltd | パルス放出型製剤 |
| FR2798289B1 (fr) | 1999-09-15 | 2004-12-31 | Cll Pharma | Formes galeniques a delitement rapide en bouche et leur procede de preparation |
| IL133196A0 (en) * | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| JP2003521507A (ja) | 2000-02-04 | 2003-07-15 | ディポメド，インコーポレイティド | ゼロ次薬物放出に接近するシェル−コア剤形 |
| US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| US6500457B1 (en) | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
| HRP20030420A2 (en) | 2000-11-30 | 2004-08-31 | Pfizer Prod Inc | Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
| DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| JP3934383B2 (ja) * | 2001-10-11 | 2007-06-20 | アルフレッサファーマ株式会社 | 経口投与用製剤 |
| US6781560B2 (en) | 2002-01-30 | 2004-08-24 | Harris Corporation | Phased array antenna including archimedean spiral element array and related methods |
| US7094427B2 (en) | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US20030224045A1 (en) | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
| ES2645930T3 (es) * | 2003-01-03 | 2017-12-11 | Supernus Pharmaceuticals, Inc. | Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas |
| US7470435B2 (en) * | 2003-11-17 | 2008-12-30 | Andrx Pharmaceuticals, Llc | Extended release venlafaxine formulation |
| ES2241478B1 (es) * | 2004-02-13 | 2006-11-16 | Lacer S.A. | Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo. |
| US9149439B2 (en) | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| AU2007201808B8 (en) | 2006-04-26 | 2013-09-05 | Sun Pharmaceutical Advanced Research Company Ltd | A method for alleviating signs and symptoms of spasticity |
| RU2009101309A (ru) | 2006-06-19 | 2010-07-27 | МакНЕЙЛ-ППС, ИНК. (US) | Частицы с энтеросолюбильным покрытием, содержащие активный ингредиент |
-
2005
- 2005-09-30 US US11/239,249 patent/US8007827B2/en not_active Expired - Fee Related
-
2006
- 2006-09-20 EP EP06825042.2A patent/EP1940361B1/en not_active Not-in-force
- 2006-09-20 JP JP2008533447A patent/JP5366549B2/ja not_active Expired - Fee Related
- 2006-09-20 CA CA2625481A patent/CA2625481C/en not_active Expired - Fee Related
- 2006-09-20 WO PCT/US2006/036694 patent/WO2007040997A2/en not_active Ceased
- 2006-09-20 CN CNA2006800432865A patent/CN101312716A/zh active Pending
- 2006-09-20 AU AU2006297477A patent/AU2006297477B2/en not_active Ceased
- 2006-09-20 BR BRPI0616703A patent/BRPI0616703A2/pt not_active IP Right Cessation
- 2006-09-20 ES ES06825042.2T patent/ES2561585T3/es active Active
- 2006-09-20 TR TR2008/04209T patent/TR200804209T1/xx unknown
- 2006-09-20 KR KR1020087010287A patent/KR20080059409A/ko not_active Ceased
- 2006-09-29 TW TW095136310A patent/TW200735899A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009510065A (ja) | 2009-03-12 |
| CN101312716A (zh) | 2008-11-26 |
| TR200804209T1 (tr) | 2008-08-21 |
| ES2561585T3 (es) | 2016-02-29 |
| CA2625481A1 (en) | 2007-04-12 |
| AU2006297477B2 (en) | 2011-02-10 |
| TW200735899A (en) | 2007-10-01 |
| CA2625481C (en) | 2012-01-03 |
| EP1940361B1 (en) | 2015-11-04 |
| US8007827B2 (en) | 2011-08-30 |
| US20060057197A1 (en) | 2006-03-16 |
| WO2007040997A2 (en) | 2007-04-12 |
| KR20080059409A (ko) | 2008-06-27 |
| EP1940361A4 (en) | 2011-03-02 |
| WO2007040997A3 (en) | 2007-09-27 |
| EP1940361A2 (en) | 2008-07-09 |
| JP5366549B2 (ja) | 2013-12-11 |
| AU2006297477A1 (en) | 2007-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0616703A2 (pt) | forma de dosagem farmacêutica | |
| DK2399579T3 (da) | Farmaceutiske doseringsformer | |
| DK2041139T3 (da) | Farmaceutiske forbindelser | |
| IL251539A0 (en) | Single pharmaceutical dosage form | |
| DK1986650T3 (da) | Manipulationssikre doserignsformer | |
| EP1992348A4 (en) | PHARMACEUTICAL COMBINATION | |
| DK1907037T4 (da) | Lægemiddeldispenser | |
| RU2398586C3 (ru) | Фармацевтическая композиция | |
| BRPI0715712A2 (pt) | Composição farmacêutica | |
| NO20075628L (no) | Farmasøytiske formuleringer | |
| BRPI0810646A2 (pt) | " compostos farmacêuticos ". | |
| BRPI0719393A2 (pt) | Composição farmacêutica | |
| DK1940467T3 (da) | Lægemiddelsammensætning med langvarig frigivelse | |
| BRPI0716445A2 (pt) | composiÇço farmacÊutica | |
| BRPI0720234A2 (pt) | Composição farmacêutica | |
| DK1957073T3 (da) | Lægemiddel | |
| DE602006013636D1 (de) | Dosiszähler | |
| BRPI0812964A2 (pt) | Forma de dosagem farmacêutica oral sólida | |
| ATE453384T1 (de) | Neue dosierformulierung | |
| BRPI0807882A2 (pt) | Forma de dosagem | |
| SI1942967T1 (sl) | Postopek za odmerjanje zdravil | |
| ZA200803152B (en) | Oramucosal pharmaceutical dosage form | |
| DK1757293T3 (da) | Bh4-responsiv hyperphenylalaninæmi-medikamenter | |
| EP1948138A4 (en) | SEGMENTED PHARMACEUTICAL FORMS | |
| ITMI20040943A1 (it) | Composizione farmaceutica cicatrizzante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA. |
|
| B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: REFERENTE A PETICAO NO 20080046461/RJ DE 28/03/2008. |
|
| B11M | Dismissal: decision cancelled |
Free format text: O DESPACHO 11.6.1 DA RPI 2195 DE 29/01/2013 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0. |
|
| B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |